The ABPI has appointed Colette Goldrick as its new Northern Ireland director and as a member of the ABPI senior leadership team.

She will be the ABPI’s first dedicated Northern Ireland director and will begin work on 12 November.

Colette, who comes from Northern Ireland herself, has a long history of working in senior roles in the pharma industry and her career includes eight years at GlaxoSmithKline in their public affairs and communications team, where she left as head of communications.

Colette also spent nine years at Pfizer in various capacities – again including a role as head of communications, corporate affairs director and head of public affairs and policy for Pfizer Europe.

Colette will be supported in her work by Marion Laverty who will help identify, establish and develop productive relationships with key opinion leaders and decision makers in Northern Ireland.

Stephen Whitehead, Chief Executive of the ABPI, said: “I am delighted that we have secured such a strong talent in Colette to build and lead the ABPI in Northern Ireland. The ABPI believes that Northern Ireland represents a significant opportunity for the bio-pharmaceutical industry in terms of the growing life science agenda, arising from world class capability at Queen's University Belfast, the University of Ulster and the Science Park.”